On December 24, 2025, Emmaus Life Sciences, Inc. entered into a License Agreement with NeoImmuneTech, granting them exclusive rights to market Endari® in the U.S. and Canada. The deal includes an upfront payment and royalties on sales, with certain conditions for the agreement to take effect.